Stockscreener 앱 받기
14.88
0.93%
-0.14
시간 외 거래:
14.90
0.02
+0.13%
전일 마감가:
$15.02
열려 있는:
$15.07
하루 거래량:
50,841
Relative Volume:
0.39
시가총액:
$197.99M
수익:
$116.26M
순이익/손실:
$-11.08M
주가수익비율:
-18.79
EPS:
-0.7917
순현금흐름:
$1.04M
1주 성능:
-0.20%
1개월 성능:
-4.31%
6개월 성능:
+50.61%
1년 성능:
+26.42%
1일 변동 폭
$14.78
$15.07
1주일 범위
$14.64
$15.37
52주 변동 폭
$7.8701
$16.24
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.88 | 199.85M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily
ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser
Anika Therapeutics Signals Momentum Amid Regulatory Risks - The Globe and Mail
Anika Therapeutics honors Clinical Trials Day as it advances patient outcomes - Traders Union
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN
Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair - Traders Union
About Us | Oil & Gas JournalAnika Therapeutics Inc.Common Stock (Nasdaq:ANIK) Stock Quote - FinancialContent
TradingKey - tradingkey.com
How Anika Therapeutics Inc. (ANIK) Affects Rotational Strategy Timing - Stock Traders Daily
Anika Therapeutics (ANIK) Eps Diluted (TTM) - Zacks Investment Research
How Anika (ANIK) margins compare to industry leaders (+0.13%) 2026-05-08High Attention Stocks - newser.com
Anika Therapeutics explores why skin heals rapidly but tendons and cartilage lag in recovery - Traders Union
Number of shareholders of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus
Anika Therapeutics Q1 2026 earnings preview - MSN
Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada
Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com
Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan
President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart
ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative
Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co
Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus
Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com Australia
Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com
Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative
Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan
Anika Therapeutics : 2026 Proxy Statement - marketscreener.com
Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union
(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey
Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan
Anika Therapeutics Inc (ANIK) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - GuruFocus
Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings - simplywall.st
Anika Therapeutics Signals Momentum Amid Regulatory Hurdles - TipRanks
Vanguard (ANIK) discloses 695,697 shares, a 5.19% stake (Schedule 13G) - Stock Titan
Anika Therapeutics (NASDAQ:ANIK) Releases Earnings Results, Misses Expectations By $0.17 EPS - MarketBeat
Anika Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Anika Therapeutics Posts Strong Q1 2026 Revenue Growth - TipRanks
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):